Sun Pharma Q2 Net Profit Rises 3% to ₹3,118 Crore
Sun Pharmaceutical Industries reported a 2.56% increase in consolidated net profit to ₹3,118 crore for the second quarter ended September 30, driven by strong performance in domestic and emerging markets.
Key Financial Highlights
- Net Profit: ₹3,118 crore (up 2.56% YoY)
- Revenue: ₹14,405 crore (up from ₹13,264 crore)
- US Sales: Innovative medicines surpassed generics for first time
Regional Performance Breakdown
India Market: Formulation sales grew 11% year-on-year to ₹47,36 crore, accounting for 33% of total consolidated sales.
US Market: Formulation sales declined 4.1% to USD 496 million, though innovative medicines showed strong growth, contributing to 30% of total sales.
Emerging Markets: Sales rose 11% to USD 325 million, representing 20% of total consolidated sales.
Rest of World: Formulation sales surged 18% to USD 234 million, accounting for 14% of total sales.
Strategic Shift to Innovation
“India, emerging markets, and the Rest of the World (market) led our growth for the period. US sales of innovative medicines have surpassed generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability,” said Kirti Ganorkar, Managing Director of Sun Pharma.
Global innovative medicines sales increased 16% year-on-year to USD 333 million, representing 20% of total consolidated sales for the quarter.
However, API sales declined 19.5% to ₹4,299 million during the July-September quarter, indicating a strategic shift toward higher-value formulations.
